Management of malignant gastrointestinal stromal tumours.

摘要: Gastrointestinal stromal tumours (GISTs) are the most common form of mesenchymal tumour gastrointestinal tract. Clinically, they range from small indolent curable with surgery alone to aggressive cancers. Making a distinction between an and malignant GIST is unreliable conventional histopathological techniques. The presence metastases at time diagnosis confirms malignancy, but all GISTs should be regarded as having potential. characteristically express KIT protein, transmembrane tyrosine kinase receptor for stem-cell factor. Most have mutation in proto-oncogene that translates into gain-of-function constitutive activation kinase. seems early tumour-promoting event pathogenesis. Commonly, show high-level primary resistance chemotherapy. Imatinib mesylate orally administered selective inhibitor certain kinases including KIT. patients advanced achieve clinical benefit significant antitumour responses imatinib mesylate. Responses been durable, tolerate drug well clinically effective doses. first systemic therapy GIST.